Alkermes (NASDAQ:ALKS – Get Score) had its goal value raised by Financial institution of America from $27.00 to $28.00 in a analysis observe issued on Sunday, The Fly studies. Financial institution of America‘s value goal would recommend a possible upside of three.28% from the corporate’s present value.
ALKS has been the topic of a lot of different analysis studies. JPMorgan Chase & Co. decreased their value goal on shares of Alkermes from $33.00 to $29.00 and set a “impartial” ranking for the corporate in a report on Tuesday, December sixth. Mizuho raised their value goal on shares of Alkermes from $34.00 to $36.00 and gave the inventory a “purchase” ranking in a report on Tuesday, November twenty second. Piper Sandler upgraded shares of Alkermes from a “impartial” ranking to an “chubby” ranking and raised their value goal for the inventory from $26.00 to $30.00 in a report on Thursday, November third. Lastly, StockNews.com downgraded shares of Alkermes from a “strong-buy” ranking to a “purchase” ranking in a analysis observe on Wednesday, November 2nd. 4 analysts have rated the inventory with a maintain ranking and 5 have assigned a purchase ranking to the inventory. In response to information from MarketBeat.com, the inventory at present has a median ranking of “Average Purchase” and a consensus goal value of $30.10.
Alkermes Inventory Up 7.1 %
Shares of ALKS traded up $1.80 throughout buying and selling hours on Friday, reaching $27.11. 2,177,675 shares of the inventory traded palms, in comparison with its common quantity of 1,148,688. The corporate has a present ratio of two.24, a fast ratio of 1.89 and a debt-to-equity ratio of 0.28. The inventory has a fifty day easy transferring common of $24.68 and a 200 day easy transferring common of $25.27. Alkermes has a 52 week low of $21.75 and a 52 week excessive of $32.79. The corporate has a market cap of $4.45 billion, a price-to-earnings ratio of -34.76 and a beta of 0.57.
Alkermes (NASDAQ:ALKS – Get Score) final launched its quarterly earnings outcomes on Wednesday, November 2nd. The corporate reported ($0.14) earnings per share for the quarter, lacking analysts’ consensus estimates of ($0.13) by ($0.01). Alkermes had a unfavorable web margin of 11.41% and a unfavorable return on fairness of 1.10%. The agency had income of $252.36 million for the quarter, in comparison with the consensus estimate of $271.45 million. Throughout the identical interval within the earlier yr, the enterprise earned ($0.02) earnings per share. The agency’s income for the quarter was down 14.2% on a year-over-year foundation. On common, equities analysts forecast that Alkermes will publish -0.31 EPS for the present yr.
Hedge Funds Weigh In On Alkermes
A number of hedge funds have just lately purchased and offered shares of the corporate. Vanguard Group Inc. grew its stake in Alkermes by 4.8% throughout the third quarter. Vanguard Group Inc. now owns 18,107,902 shares of the corporate’s inventory valued at $404,350,000 after buying a further 828,769 shares within the final quarter. BlackRock Inc. lifted its place in Alkermes by 5.8% throughout the first quarter. BlackRock Inc. now owns 15,080,046 shares of the corporate’s inventory valued at $396,756,000 after buying a further 827,759 shares over the past quarter. State Avenue Corp lifted its place in Alkermes by 9.4% throughout the third quarter. State Avenue Corp now owns 6,467,201 shares of the corporate’s inventory valued at $144,413,000 after buying a further 556,097 shares over the past quarter. Hardman Johnston International Advisors LLC lifted its place in Alkermes by 7.0% throughout the third quarter. Hardman Johnston International Advisors LLC now owns 5,734,259 shares of the corporate’s inventory valued at $128,046,000 after buying a further 376,543 shares over the past quarter. Lastly, Renaissance Applied sciences LLC lifted its place in Alkermes by 4.4% throughout the third quarter. Renaissance Applied sciences LLC now owns 5,556,113 shares of the corporate’s inventory valued at $124,068,000 after buying a further 233,500 shares over the past quarter. Hedge funds and different institutional buyers personal 96.15% of the corporate’s inventory.
Alkermes Firm Profile
Alkermes plc, a biopharmaceutical firm, researches, develops, and commercializes pharmaceutical merchandise to deal with unmet medical wants of sufferers in varied therapeutic areas in the USA, Eire, and internationally. Its marketed merchandise embrace ARISTADA, an intramuscular injectable suspension for the therapy of schizophrenia; VIVITROL for the therapy of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the therapy of schizophrenia and bipolar I dysfunction; INVEGA SUSTENNA for the therapy of schizophrenia and schizoaffective dysfunction; XEPLION, INVEGA TRINZA, and TREVICTA to deal with schizophrenia and schizoaffective; and VUMERITY for the therapy of relapsing types of a number of sclerosis in adults, together with clinically remoted syndrome, relapsing-remitting and energetic secondary progressive illnesses.
This on the spot information alert was generated by narrative science know-how and monetary information from MarketBeat in an effort to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to [email protected].
Earlier than you take into account Alkermes, you will wish to hear this.
MarketBeat retains monitor of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they suggest to their purchasers every day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Alkermes wasn’t on the checklist.
Whereas Alkermes at present has a “Average Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.